AACR 2023 – Regeneron tries again in multiple myeloma
If at first you don’t succeed... Regeneron follows the underwhelming linvoseltamab with something it hopes will be better.
Remarkably, interest in BCMA continues
But, as Celyad bows out, how do you compete in a field as crowded as this?
J&J’s $5bn projects have much to prove
The group highlighted Carvykti, nipocalimab and milvexian among its potential mega-blockbusters.
Asco 2022 movers – cell therapy wins, but it’s not the whole story
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
Asco 2022 – Carvykti casts a long shadow
Arcellx, Gracell and Oricell work hard to prove that there is still space for new Car-T therapies in multiple myeloma.